Last reviewed · How we verify

NCT04005833: FIBRO-COPD

Blood Fibrocytes During an Exacerbation and Lung Function Decline in Patients With COPD in Primary Care.

Terminated Last updated 23 August 2024
What this trial tests

trial testing spirometry in Chronic Obstructive Pulmonary Disease in 32 participants. Terminated before completion.

Timeline
24 September 2019
Primary endpoint
9 March 2021
9 June 2021

Quick facts

Lead sponsorUniversity Hospital, Bordeaux
StatusTerminated
Study typeOBSERVATIONAL
Enrollment32
Start date24 September 2019
Primary completion9 March 2021
Estimated completion9 June 2021
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Bordeaux

Who can join

40 and older, any sex, with Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to estimate the association between blood fibrocytes measured during a suspected exacerbation and 3-year decline forced expiratory volume in one second (FEV1), in patients with Chronic obstructive pulmonary disease (COPD) in primary care, with a history of smoking, independently of the number of exacerbations and of tobacco or occupational exposure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of spirometry

Trials testing the same drug.

Other recruiting trials for Chronic Obstructive Pulmonary Disease

Currently open trials in the same condition.

Other University Hospital, Bordeaux trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04005833.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing